10 results on '"Senff NJ"'
Search Results
2. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers.
- Author
-
Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, and Willemze R
- Published
- 2007
3. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.
- Author
-
Koens L, Senff NJ, Vermeer MH, Willemze R, and Jansen PM
- Subjects
- Aged, Aged, 80 and over, B-Lymphocytes immunology, B-Lymphocytes pathology, B-Lymphocytes virology, Biomarkers, Tumor analysis, DNA, Viral isolation & purification, Diagnosis, Differential, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Infections pathology, Epstein-Barr Virus Infections virology, Female, Herpesvirus 4, Human genetics, Herpesvirus 4, Human isolation & purification, Humans, Immunohistochemistry, Immunophenotyping, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Lymphoma, B-Cell virology, Male, Middle Aged, Phenotype, Predictive Value of Tests, Risk Factors, Skin immunology, Skin pathology, Skin virology, Skin Neoplasms immunology, Skin Neoplasms pathology, Skin Neoplasms virology, Time Factors, B-Lymphocytes drug effects, Cell Proliferation drug effects, Epstein-Barr Virus Infections chemically induced, Immunosuppressive Agents adverse effects, Lymphoma, B-Cell chemically induced, Methotrexate adverse effects, Skin drug effects, Skin Neoplasms chemically induced
- Abstract
Methotrexate (MTX)-associated B-cell lymphoproliferative disorders (B-LPD) may first present in the skin, but their clinicopathologic features are still ill defined. Differentiation from primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) is important, as MTX-associated B-LPD may show spontaneous regression after withdrawal of MTX therapy. In the present study, the clinicopathologic and phenotypical features of 10 patients with MTX-associated B-LPD first presenting in the skin, including 5 EBV(+) and 5 EBV(-) cases, were investigated. Six patients had skin-limited disease. Clinically, abrogation of MTX therapy resulted in a complete response in 4 cases and a partial response in another 2. The 5-year disease-specific survival was 90%. MTX-associated B-LPD differed from primary cutaneous follicle center lymphoma by the presence of ulcerating and/or generalized skin lesions, an infiltrate composed of centroblasts/immunoblasts rather than large centrocytes, reduced staining for CD79a, and expression of BCL2, IRF4, and FOXP1 in most cases. EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV. EBV(-) cases showed morphologic and immunophenotypical similarities to PCLBCL-LT but differed by presentation with generalized skin lesions in 4 of 5 cases. The results of this study, showing a relatively good clinical outcome and spontaneous disease regression after only withdrawal of MTX in a considerable proportion of patients, underscores the importance of a careful wait-and-see policy before considering more aggressive therapies in patients with MTX-associated B-LPD of the skin.
- Published
- 2014
- Full Text
- View/download PDF
4. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.
- Author
-
Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, and Noordijk EM
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Lymphoma, B-Cell classification, Lymphoma, B-Cell pathology, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone radiotherapy, Lymphoma, T-Cell, Cutaneous classification, Lymphoma, T-Cell, Cutaneous pathology, Male, Middle Aged, Mycosis Fungoides pathology, Mycosis Fungoides radiotherapy, Radiotherapy Dosage, Remission Induction, Skin Neoplasms classification, Skin Neoplasms pathology, Young Adult, Lymphoma, B-Cell radiotherapy, Lymphoma, T-Cell, Cutaneous radiotherapy, Skin Neoplasms radiotherapy
- Abstract
Purpose: To determine the efficacy of low-dose palliative radiotherapy for both low-grade malignant cutaneous B-cell lymphomas (CBCLs) and cutaneous T-cell lymphomas (mycosis fungoides)., Methods and Materials: A total of 18 patients with low-grade CBCL (10 primary cutaneous marginal zone B-cell and 8 primary cutaneous follicle center lymphomas) with 44 symptomatic plaques and tumors underwent low-dose (4 Gy in two fractions) local radiotherapy. A total of 31 patients with mycosis fungoides were treated at 82 symptomatic sites, initially with 4 Gy and later with 8 Gy in two fractions., Results: The complete response rate for CBCL lesions was 72%. Of the 44 B-cell lymphoma lesions, 13 were re-treated to the same site after a median of 6.3 months because of persistent (n = 8) or recurrent (n = 5) symptomatic disease. Of the mycosis fungoides patients treated with 4 Gy in two fractions (17 lesions), 70% failed to respond. Increasing the dose to 8 Gy in two fractions yielded a complete response rate of 92% (60 of 65 lesions). The patients in whom low-dose radiotherapy failed were retreated with 20 Gy in eight fractions., Conclusion: Our results have demonstrated that low-dose involved-field radiotherapy induces a high response rate in both CBCL and cutaneous T-cell lymphoma lesions without any toxicity. Therefore, this treatment is now our standard palliative treatment. At progression, it is safe and feasible to apply greater radiation doses.
- Published
- 2009
- Full Text
- View/download PDF
5. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type.
- Author
-
Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, Espinet B, de Misa Cabrera RF, Geerts ML, Kempf W, Mitchell TJ, Paulli M, Petrella T, Pimpinelli N, Santucci M, Whittaker SJ, Willemze R, and Tensen CP
- Subjects
- Aged, Aged, 80 and over, DNA Methylation genetics, Female, Gene Deletion, Humans, Leg, Male, Middle Aged, Prognosis, Reproducibility of Results, Chromosome Mapping, Chromosomes, Human, Pair 9 genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse genetics, Skin Neoplasms diagnosis, Skin Neoplasms genetics
- Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) is the most aggressive type of primary cutaneous B-cell lymphoma. In a recent study on 12 patients it was found that inactivation of CDKN2A by either deletion of 9p21.3 or promoter hypermethylation is correlated with a worse prognosis. In the present EORTC multicenter study, skin biopsies of 64 PCLBCL, LT patients were analyzed by multiplex ligation-dependent probe amplification to validate these previous results and to fine-map the losses in this region. Although no minimal common region of loss could be identified, most homozygous loss was observed in the CDKN2A gene (43 of 64; 67%) encoding p16 and p14ARF. Promoter hypermethylation of p16 and p14ARF was found in six and zero cases, respectively. Survival was markedly different between patients with versus without aberrations in the CDKN2A gene (5-year disease-specific survival 43 versus 70%; P=0.06). In conclusion, our results confirm that deletion of chromosome 9p21.3 is found in a considerable proportion of PCLBCL, LT patients and that inactivation of the CDKN2A gene is associated with an unfavorable prognosis. In most patients the deletion involves a large area of at least several kilobase pairs instead of a small minimal common region.
- Published
- 2009
- Full Text
- View/download PDF
6. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
- Author
-
Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, and Willemze R
- Subjects
- Anti-Bacterial Agents therapeutic use, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents therapeutic use, Humans, Interferon Type I administration & dosage, Lyme Disease complications, Lyme Disease drug therapy, Lymphoma, B-Cell complications, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell pathology, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone therapy, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse therapy, Neoplasm Staging methods, Radiotherapy Dosage, Recombinant Proteins, Rituximab, Skin Neoplasms complications, Skin Neoplasms diagnosis, Skin Neoplasms pathology, Lymphoma, B-Cell therapy, Skin Neoplasms therapy
- Abstract
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
- Published
- 2008
- Full Text
- View/download PDF
7. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma.
- Author
-
Senff NJ, Kluin-Nelemans HC, and Willemze R
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Bone Marrow Examination, Female, Humans, Lymphoma, B-Cell mortality, Lymphoma, B-Cell, Marginal Zone mortality, Lymphoma, B-Cell, Marginal Zone pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Skin Neoplasms mortality, Young Adult, Bone Marrow pathology, Lymphoma, B-Cell pathology, Skin Neoplasms pathology
- Abstract
Whether or not bone marrow biopsies should be performed routinely in patients with skin lesions that show histological features consistent with an indolent B-cell lymphoma [marginal zone lymphoma (MZL) or follicle centre lymphoma (FCL)] has been debated. As no studies have addressed this question for this group of lymphomas, we evaluated the results of bone marrow biopsy examination in 275 patients with histological features consistent with MZL (n = 82) or FCL (n = 193) first presenting in the skin. In the MZL group, two of 82 patients (2%) showed bone marrow involvement, which was the only extracutaneous localization in one of these patients. In the FCL group, 22 of 193 patients (11%) had bone marrow involvement and was the only extracutaneous localization in nine of them. FCL patients with skin lesions and a positive bone marrow had a significantly worse prognosis when compared with patients with only skin lesions (5-year disease-specific survival 63% vs. 95%; P = 0.001). These results indicate that bone marrow investigation is essential for staging patients with a FCL first presenting in the skin. Bone marrow examination appears to have limited value in patients with MZL presenting in the skin.
- Published
- 2008
- Full Text
- View/download PDF
8. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
- Author
-
Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JL, Robson A, Senff NJ, Vermeer MH, Wechsler J, Whittaker S, and Meijer CJ
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, CD4 Antigens metabolism, CD56 Antigen metabolism, CD8 Antigens metabolism, Carrier Proteins metabolism, Child, Diagnosis, Differential, Disease-Free Survival, Education, Female, Humans, Lymphoma, T-Cell, Cutaneous drug therapy, Lymphoma, T-Cell, Cutaneous metabolism, Lymphoma, T-Cell, Cutaneous pathology, Male, Microfilament Proteins metabolism, Middle Aged, Panniculitis drug therapy, Panniculitis metabolism, Panniculitis pathology, Phenotype, Receptors, Antigen, T-Cell, alpha-beta metabolism, Receptors, Antigen, T-Cell, gamma-delta metabolism, Survival Rate, T-Lymphocytes metabolism, T-Lymphocytes pathology, Lymphoma, T-Cell, Cutaneous classification, Lymphoma, T-Cell, Cutaneous diagnosis, Lymphoma, T-Cell, Cutaneous mortality, Panniculitis classification, Panniculitis diagnosis, Panniculitis mortality
- Abstract
In the WHO classification, subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behavior. Recent studies suggest that distinction should be made between SPTL with an alpha/beta T-cell phenotype (SPTL-AB) and SPTL with a gammadelta T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-ABs and 20 SPTL-GDs were studied at a workshop of the EORTC Cutaneous Lymphoma Group. SPTL-ABs were generally confined to the subcutis, had a CD4-, CD8+, CD56-, betaF1+ phenotype, were uncommonly associated with a hemophagocytic syndrome (HPS; 17%), and had a favorable prognosis (5-year overall survival [OS]: 82%). SPTL-AB patients without HPS had a significantly better survival than patients with HPS (5-year OS: 91% vs 46%; P<.001). SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4-, CD8-, CD56+/-, betaF1- T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment. These results indicate that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further be used only for SPTL-AB. SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned.
- Published
- 2008
- Full Text
- View/download PDF
9. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.
- Author
-
Senff NJ and Willemze R
- Subjects
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Cohort Studies, Female, Humans, Lymphoma, B-Cell classification, Male, Middle Aged, Retrospective Studies, Skin Neoplasms classification, Biomarkers, Tumor analysis, Lymphoma, B-Cell pathology, Neoplasm Staging methods, Skin Neoplasms pathology
- Abstract
Background: Recently, a consensus proposal was published for a TNM classification system for all primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome, meant to document extent of disease in a consistent manner. The applicability and the prognostic significance of this system have not been investigated thus far., Objectives: To test the applicability and prognostic relevance of the proposed TNM classification system on a cohort of primary cutaneous B-cell lymphomas (CBCL)., Methods: The study group included 71 primary cutaneous marginal zone lymphomas (PCMZL), 171 primary cutaneous follicle centre lymphomas (PCFCL) and 58 primary cutaneous diffuse large B-cell lymphomas, leg type (PCLBCL, LT). As only patients with primary cutaneous lymphoma were included (T1-3, N0M0), only the T-rating was scored. The results were compared with the scoring as applied by the Dutch Cutaneous Lymphoma Group., Results: The system was easily applicable to all cases. In PCMZL and PCFCL no correlation was found between T-score and survival (5-year disease-specific survival: T1, 100% and 98%; T2, 94% and 93%; T3, 100% and 88%, respectively). In PCLBCL, LT there was a clear, although statistically not significant, association between increasing T-score and reduced survival (5-year disease-specific survival: T1, 75%; T2, 49%; T3, 0%; P = 0.077). Comparing the TNM system with the Dutch Cutaneous Lymphoma Group system, there was a discrepancy in the classification of 20 cases., Conclusions: The new TNM system is a useful tool to document disease extent in patients with CBCL and provides prognostic information in the group of patients with PCLBCL, LT.
- Published
- 2007
- Full Text
- View/download PDF
10. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
- Author
-
Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, and Willemze R
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Incidence, Lymphoma classification, Lymphoma radiotherapy, Lymphoma, Follicular classification, Lymphoma, Follicular radiotherapy, Male, Middle Aged, Neoplasm Recurrence, Local epidemiology, Remission Induction, Retrospective Studies, Survival Analysis, Lymphoma, B-Cell classification, Lymphoma, B-Cell radiotherapy, Skin Neoplasms classification, Skin Neoplasms radiotherapy, World Health Organization
- Abstract
Objective: To evaluate the results of radiotherapy in patients with primary cutaneous B-cell lymphoma (CBCL) classified according to the criteria of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification., Design: Multicenter, 20-year, retrospective, cohort analysis., Setting: Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma Group., Patients: From 1985 until 2005, a total of 153 patients with CBCL were initially treated with radiotherapy with curative intent. These cases were classified according to the WHO-EORTC classification and consisted of 25 primary cutaneous marginal zone lymphomas (PCMZLs), 101 primary cutaneous follicle center lymphomas (PCFCLs), and 27 primary cutaneous large B-cell lymphomas, leg type (PCLBCLs, LT). Interventions Local radiotherapy with a median dose of 40 Gy (range, 20-46 Gy) applied to all visible skin lesions., Main Outcome Measures: Complete remission rate, relapse rate, 5-year relapse-free survival, 5-year overall survival, and 5-year disease-specific survival., Results: Complete remission was reached in 151 of 153 patients (99%). Relapse rates for PCMZL, PCFCL, and PCLBCL, LT were 60%, 29%, and 64%, and the 5-year disease-specific survival was 95%, 97%, and 59%, respectively. The PCFCLs presenting on the legs had a higher relapse rate (63%) and a much lower 5-year disease-specific survival (44%) than PCFCLs at other sites (relapse rate, 25%; 5-year disease-specific survival, 99%)., Conclusions: Radiotherapy is a suitable treatment for a large group of patients with CBCL. However, patients with PCFCL presenting with lesions on the leg and patients with PCLBCL, LT display a more unfavorable clinical course and should therefore be treated with more aggressive treatment modalities.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.